High cyclooxygenase-2 expression in cervical adenocarcinomas

Gynecologic Oncology

Volumn 88, Issue 3, 2003, Pages 379-385

  Chen, Yi Jen ^a   Wang, Liang Shun ^a   Wang, Peng Hui ^a   Lai, Chiung Ru ^a   Yen, Ming Shyen ^a   Ng, Heung Tat ^a   Yuan, Chiou Chung ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Adenocarcinoma; Cervical cancer; Cyclooxygenase (COX 2); Squamous cell carcinoma

Indexed keywords

CYCLOOXYGENASE 2; POLYCLONAL ANTIBODY;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERUS MYOMA;

EID: 0037342351     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(02)00066-5     Document Type: Article

References (39)

1. Schoell W.M.J., Janicek M.R., Mirhashemi R. Epidemiology and biology of cervical cancer. Semin Surg Oncol. 16:1999;203-211.
2. Smith W.L., Garavito R.M., DeWitt E.L. Prostaglandin endoperoxide H synthases COX-1 and -2. J Biol Chem. 2731:1996;33157-33160.
3. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cycloogygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
4. Tsujii M., DuBois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell. 83:1995;493-501.
5. Subbaramaiah K., Telang N., Ramonetti J.T., Araki R., Devito B., Weksler B.B., Dannenberg A.J. Transcription of COX-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56:1996;4424-4429.
6. Reddy B.S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug during different stages of rat colon tumor development. Cancer Res. 47:1987;5340-5346.
7. Rubio C.A. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer. 58:1986;1116-1119.
8. Castonguay A., Rioux N. Inhibition of lung tumorigenesis by sulindac. Comparison of two experimental protocols. Carcinogenesis. 18:1997;491-496.
9. McCormick D.L., Moon R.C. Inhibition of mammary carcinogenesis by flurbiprogen, a non-steroidal anti-inflammatory agent. Br J Cancer. 48:1983;859-861.
10. Giovanucci E., Egan K.M., Hunter D.J., Stampger M.J., Colditz G.A., Willett W.C., Speizer F.E. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 333:1995;609-614.
11. Funkhouser E.M., Sharp G.B. Aspirin and reduced risk of esophageal cancer. Cancer. 76:1995;1116-1119.
12. Kulkarni S., Rader J.S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., Subbaramaiah K., Dannenberg A.J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 7:2001;429-434.
13. Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol. 76:2000;320-325.
14. Gaffney D.K., Holden J., Davis M., Zempolich K., Murphy K.J., Dodson M. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 49:2001;1213-1217.
15. Yuan C.C., Wang P.H., Lai C.R., Yen M.S., Chen C.Y., Juang C.M. Prognosis-predicting system based on factors related to survival of cervical carcinoma. Int J Gynecol Obstet. 63:1998;163-167.
16. Yuan C.C., Wang P.H., Lai C.R., Tsu E.J., Yen M.S., Ng H.T. Recurrence and survival of 1,115 cervical cancer patients treated with radical hysterectomy. Gynecol Obstet Invest. 47:1999;127-132.
17. Rosai J. Ackerman's surgical pathology. 8th ed:1996;Mosby, St. Louis.
18. Remmele W., Schicketanz K.H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs subjective grading (IRS). Pathol Res Pract. 8:1993;227-245.
19. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., Koki A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 89:2000;2637-2645.
20. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 58:1998;3761-3764.
21. Williams C.S., Smalley W., DuBois R.N. Aspirin use and potential mechanisms of colorectal cnacer prevention. J Clin Invest. 100:1997;1325-1329.
22. Berek J.S., Hacker N.F., Fu Y.S., Sokale J.R., Leuchter R.C., Lagasse L.D. Adenocarcinoma of the uterine cervix histologic variables associated with lymph node metastasis and survival . Obstet Gynecol. 65:1985;46-52.
23. Hopkins M.P., Morley G.W. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol. 77:1991;912-917.
24. Milas L., Kishi K., Hunter N., Eta I. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst. 91:1999;1501-1504.
25. Kishi K., Petersen S., Petersen C., Hunter N., Mason K., Masferrer J.L., Tofilon P.J., Milas L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 60:2000;1326-1331.
26. Steinauer K.K., Gibbs I., Ning S., French J.N., Armstrong J., Knox S.J. Radiation induces upregulation of cycloxygenase-2 protein in PC-3 cells. Int J Radiat Oncol Biol Phys. 48:2000;325-328.
27. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001.
28. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induce by colon cancer cells. Cell. 93:1998;705-716.
29. Stolina M., Sharma S., Lin Y., Dohadwala M., Gardner B., Luo J., Zhy L., Kronenberg M., Miller P.W., Portanova J., Lee J.C., Dubinett S.M. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 164:2000;361-370.
30. Liu X.H., Yao S., Kirschenbaum A., Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and downregulates bcl-2 expression in LNCap cells. Cancer Res. 10:1998;4245-4249.
31. Dewitt D., Smith W.L. Yes, but do they still get headaches? Cell. 83:1995;345-348.
32. Rao A.R., Hussain S.P. Modulation of methylcholanthrene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett. 43:1988;15-19.
33. Langman M.J., Jensen D.M., Watson D.J., Harper S.E., Zhao P.L., Quan H., Bolognese J.A., Simon T.J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc. 282:1999;1929-1933.
34. Kavamori T., Rao C.V., Seibert K., Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxybenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
35. Okajima E., Denda A., Ozono S., Takahama M., Akai H., Sasaki Y., Kitayama W., Wakabayashi K., Konishi Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res. 58:1998;3028-3031.
36. Harris R.E., Alshafie G.A., Abou-Issa H., Seibert K. Chemoprevention of breast cancer in rates by celecoxib, a cycloxygenase 2 inhibitor. Cancer Res. 60:2000;2101-2103.
37. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F., Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 164:2000;820-825.
38. Hong W.K., Sporn M.B. Recent advances in chemoprevention of cancer. Science. 278:1994;1073-1077.
39. Ferrandina G., Lauriola L., Distefano M.G., Zannoni G.F., Gessi M., Legge F., Maggiano N., Mancuso S., Capelli A., Scambia G., Ranelletti F.O. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol. 20:(4):2002;973-981.